FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide
Leading supply chain visibility company FourKites and RCS Logistics, one of the world’s leading independent logistics service providers, today announced a partnership to provide RCS customers with a one-stop shop for end-to-end visibility into their shipments across ocean, air, drayage, intermodal and over-the-road (OTR). Leveraging FourKites’ industry-leading real-time supply chain data, RCS’s internal teams and customers are benefiting from automated, real-time visibility into the status and location of shipments in transit and at rest, all over the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005067/en/
FourKites and RCS Logistics Partner to Bring End-to-End Multimodal Visibility to Customers Worldwide (Photo: Business Wire)
“FourKites’ supply chain visibility platform is a game-changer for RCS Logistics,” says Brian Heaney, President at RCS Logistics. “By providing comprehensive end-to-end visibility data, the industry’s most accurate predictive ETAs and real-time status into shipments, our internal teams are much more efficient and able to focus on higher-value services, while our customers and partners receive a holistic view of their supply chain and shipments. It’s a modern, world-class experience that every stakeholder — large and small — can now enjoy.”
Since deploying the FourKites platform — including the company’s Dynamic Ocean ® solution — in Q3 2022 to track ocean, drayage and OTR shipments, RCS has achieved 7x growth in its domestic transport services, while its ocean freight business has grown 12x. “We are known in the industry as a leading air freight forwarder,” notes Brian Aldridge, SVP Sales, at RCS. “With FourKites, we’ve been able to elevate our ocean freight experience, and connect the dots with other modes, to truly differentiate ourselves in the market. Our customers and partners appreciate FourKites’ simple, modern interface, and the transparency it creates across their supply chain.”
With FourKites in place, track-and-trace teams, drayage providers and warehouse staff have been alleviated of time-consuming manual tracking processes. Moreover, RCS’s data analysts are leveraging FourKites’ advanced analytics — which provide insights into on-time performance, dwell and detention costs, tracking quality, lane and mode performance, and more — to drive continuous improvements in every aspect of the company’s operations.
“We are thrilled to partner with a leader like RCS Logistics, which shares our vision for automated, interconnected and collaborative digital global supply chains, end to end,” says Brad Klaus, Group Vice President, International Solutions, at FourKites. “Our work together illustrates how we integrate across the supply chain ecosystem to modernise operations and provide a superior customer experience in the process.”
Building on the success it has seen to date with ocean, drayage and OTR shipment visibility, the two companies are now working to bring greater visibility to RCS Logistics’ leading door-to-door international air freight forwarding solutions.
About RCS Logistics
RCS Logistics is one of the world’s leading logistics providers specializing in international air, ocean and land freight forwarding, supply chain management, 3PL, trucking transportation, distribution, customs brokerage, and other logistics solutions. To learn more, visit http://www.rcslogistics.com/.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005067/en/
Contact information
Scott Johnston
European PR Director FourKites
+31 62 147 8442
sscott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
